首页> 外文期刊>Journal of Investigative Medicine High Impact Case Reports >Response of Bortezomib Chemotherapy in Hepatic Amyloidosis
【24h】

Response of Bortezomib Chemotherapy in Hepatic Amyloidosis

机译:硼替佐米化疗对肝淀粉样变的反应

获取原文
       

摘要

Amyloidosis is a rare disorder with a wide spectrum of presentations and anomalies. It is subdivided into 2 broad categories based on protein deposition; primary and secondary amyloidosis. It can present as a single-organ involvement or as a diffuse infiltrative multi-organ process. Isolated hepatic amyloidosis presentation is a rare phenomenon that develops due to insoluble amyloid deposition in liver. Its clinical presentation is usually vague and ranges from mild hepatomegaly with elevated liver enzymes to acute liver failure and hepatic rupture. Currently, there are scarce data available regarding treatment options for biopsy-proven hepatic amyloidosis. In this review article, we present an interesting case of hepatic amyloidosis and its poor outcome to new molecular targeted chemotherapy. Furthermore, we aim to review current and future diagnostic tools for early detection and advancements in targeted chemotherapeutics options available for hepatic amyloidosis.
机译:淀粉样变性病是一种罕见的疾病,表现形式和异常现象广泛。根据蛋白质沉积,它分为两大类;原发性和继发性淀粉样变性。它可以表现为单器官参与或弥漫性浸润多器官过程。由于肝脏中不溶性淀粉样蛋白沉积,孤立的肝淀粉样变性病表现是一种罕见的现象。它的临床表现通常是模糊的,范围从轻度肝肿大,肝酶升高到急性肝衰竭和肝破裂。当前,有关活检证实的肝淀粉样变性病的治疗选择的数据很少。在这篇综述文章中,我们提出了一个有趣的案例,即肝淀粉样变性及其对新型分子靶向化疗的不良预后。此外,我们旨在审查当前和将来的诊断工具,以早期发现和发展针对肝淀粉样变性的靶向化学治疗方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号